1.975

6.15% 0.105

Iovance Biotherapeutics Inc (IOVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IOVA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.87

Aprire:

$1.96

Volume 24 ore:

8.05M

Relative Volume:

0.61

Capitalizzazione di mercato:

$666.20M

Reddito:

$32.77M

Utile/perdita netta:

$-440.22M

Rapporto P/E:

-1.1826

EPS:

-1.67

Flusso di cassa netto:

$-400.48M

1 W Prestazione:

+16.76%

1M Prestazione:

-11.38%

6M Prestazione:

-66.30%

1 anno Prestazione:

-77.26%

Intervallo 1D:

$1.945

$2.15

Intervallo di 1 settimana:

$1.69

$2.15

Portata 52W:

$1.6385

$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Nome

Iovance Biotherapeutics Inc

Settore

Healthcare (1167)

Industria

Biotechnology (655)

Telefono

(650) 260-7120

Indirizzo

825 INDUSTRIAL ROAD, SAN CARLOS

Dipendente

838

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

IOVA's Discussions on Twitter

Confronta IOVA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IOVA Iovance Biotherapeutics Inc	1.995	567.69M	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	474.04	117.98B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	567.75	58.10B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	318.25	42.26B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	564.23	33.42B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	252.86	26.08B	3.81B	-644.79M	-669.77M	-6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-16	Downgrade	UBS	Buy → Neutral
2025-05-12	Downgrade	Truist	Buy → Hold
2025-05-09	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Iniziato	UBS	Buy
2024-07-29	Downgrade	Piper Sandler	Overweight → Neutral
2023-11-20	Iniziato	Goldman	Buy
2023-09-18	Reiterato	Barclays	Overweight
2023-05-30	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-27	Ripresa	Wells Fargo	Equal Weight
2023-01-27	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-12-09	Downgrade	Goldman	Buy → Neutral
2022-10-31	Iniziato	Guggenheim	Neutral
2022-08-18	Ripresa	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Stifel	Hold → Buy
2021-12-07	Ripresa	Cowen	Outperform
2021-06-10	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Downgrade	Piper Sandler	Overweight → Neutral
2021-05-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Downgrade	Stifel	Buy → Hold
2021-05-03	Iniziato	Truist	Buy
2021-04-16	Iniziato	Goldman	Buy
2021-03-08	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-15	Downgrade	H.C. Wainwright	Buy → Neutral
2020-10-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-22	Iniziato	Mizuho	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-02-26	Reiterato	Oppenheimer	Outperform
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-10-01	Iniziato	Stifel	Buy
2019-04-29	Iniziato	Piper Jaffray	Overweight
2019-02-28	Reiterato	Chardan Capital Markets	Buy
2019-02-07	Iniziato	Robert W. Baird	Outperform
2018-12-31	Ripresa	B. Riley FBR	Buy
2018-07-06	Reiterato	Chardan Capital Markets	Buy
2018-04-10	Aggiornamento	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Reiterato	B. Riley FBR, Inc.	Neutral
2018-02-23	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Reiterato	H.C. Wainwright	Buy
2017-11-01	Reiterato	B. Riley FBR, Inc.	Buy

Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

08:26 AM

Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener

08:26 AM

07:41 AM

Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients - Quiver Quantitative

07:41 AM

04:57 AM

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire

04:57 AM

03:49 AM

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener

03:49 AM

Jul 13, 2025

IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve

Jul 13, 2025

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire

Jul 13, 2025

2025-07-13 | Investor Alert: Deadline Approaching to Join Iovance Biotherapeutics, Inc. (IOVA) Class ActionContact Levi & Korsinsky | NDAQ:IOVA | Press Release - Stockhouse

Jul 13, 2025

Iovance Biotherapeutics Sued for Securities Law ViolationsInvestors Should Contact Faruqi & Faruqi for More InformationIOVA - StreetInsider

Jul 13, 2025

Jul 12, 2025

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Jul 12, 2025

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 12, 2025

IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action – IOVA - TradingView

Jul 12, 2025

IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns - GlobeNewswire

Jul 12, 2025

IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop - GlobeNewswire

Jul 12, 2025

Jul 11, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - Morningstar

Jul 11, 2025

Investors who lost money on Iovance Biotherapeutics, Inc. - GlobeNewswire

Jul 11, 2025

Jul 10, 2025

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy - GlobeNewswire

Jul 10, 2025

Jul 09, 2025

Iovance Biotherapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. July 14, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire

Jul 09, 2025

IOVA DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, - GlobeNewswire

Jul 09, 2025

Jul 07, 2025

Shareholders that lost money on Iovance Biotherapeutics, - GlobeNewswire

Jul 07, 2025